229 related articles for article (PubMed ID: 21822036)
1. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
[TBL] [Abstract][Full Text] [Related]
2. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging.
Bakavicius A; Daniunaite K; Zukauskaite K; Barisiene M; Jarmalaite S; Jankevicius F
Clin Epigenetics; 2019 Aug; 11(1):115. PubMed ID: 31383039
[TBL] [Abstract][Full Text] [Related]
3. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract][Full Text] [Related]
4. The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients.
Haluskova J; Lachvac L; Nagy V
Bratisl Lek Listy; 2015; 116(2):79-82. PubMed ID: 25665470
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of RASSF1 promoter methylation in prostate cancer.
Daniunaite K; Jarmalaite S; Kalinauskaite N; Petroska D; Laurinavicius A; Lazutka JR; Jankevicius F
J Urol; 2014 Dec; 192(6):1849-55. PubMed ID: 24980613
[TBL] [Abstract][Full Text] [Related]
6. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract][Full Text] [Related]
7. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of DNA methylation in multifocal prostate cancer.
Serenaite I; Daniunaite K; Jankevicius F; Laurinavicius A; Petroska D; Lazutka JR; Jarmalaite S
Virchows Arch; 2015 Jan; 466(1):53-9. PubMed ID: 25369892
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A
Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176
[TBL] [Abstract][Full Text] [Related]
10. Meta-analyses of methylation markers for prostate cancer.
Jiang D; Shen Y; Dai D; Xu Y; Xu C; Zhu H; Huang T; Duan S
Tumour Biol; 2014 Oct; 35(10):10449-55. PubMed ID: 25053593
[TBL] [Abstract][Full Text] [Related]
11. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
12. Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
Walter RFH; Rozynek P; Casjens S; Werner R; Mairinger FD; Speel EJM; Zur Hausen A; Meier S; Wohlschlaeger J; Theegarten D; Behrens T; Schmid KW; Brüning T; Johnen G
PLoS One; 2018; 13(5):e0195716. PubMed ID: 29851970
[TBL] [Abstract][Full Text] [Related]
13. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
Clark JP; Munson KW; Gu JW; Lamparska-Kupsik K; Chan KG; Yoshida JS; Kawachi MH; Crocitto LE; Wilson TG; Feng Z; Smith SS
Clin Chem; 2008 Dec; 54(12):2007-17. PubMed ID: 18948370
[TBL] [Abstract][Full Text] [Related]
14. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of GSTP1, RASSF1, AND RASSF2 Methylation in Serum of Prostate Cancer Patients.
Aykanli E; Arisan S; Arisan ED; Yavuzsan AH
Urol J; 2024 May; 21(3):182-188. PubMed ID: 38493315
[TBL] [Abstract][Full Text] [Related]
16. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.
Rogers CG; Gonzalgo ML; Yan G; Bastian PJ; Chan DY; Nelson WG; Pavlovich CP
J Urol; 2006 Nov; 176(5):2280-4. PubMed ID: 17070312
[TBL] [Abstract][Full Text] [Related]
17. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer.
Woodson K; O'Reilly KJ; Hanson JC; Nelson D; Walk EL; Tangrea JA
J Urol; 2008 Feb; 179(2):508-11; discussion 511-2. PubMed ID: 18076912
[TBL] [Abstract][Full Text] [Related]
18. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
[TBL] [Abstract][Full Text] [Related]
19. Altered methylation of multiple genes in carcinogenesis of the prostate.
Yamanaka M; Watanabe M; Yamada Y; Takagi A; Murata T; Takahashi H; Suzuki H; Ito H; Tsukino H; Katoh T; Sugimura Y; Shiraishi T
Int J Cancer; 2003 Sep; 106(3):382-7. PubMed ID: 12845678
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.
Gonzalgo ML; Pavlovich CP; Lee SM; Nelson WG
Clin Cancer Res; 2003 Jul; 9(7):2673-7. PubMed ID: 12855646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
